Condition: HIV Infections · PLWH · ART · Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
This is a phase I, randomized, double-blind, placebo-controlled clinical trial to investigate the safety of VRC07-523LS and PGDM1400LS in combination with ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv4 and A244d11gp120/ALFQ vaccination, and the impact on viral load setpoint during analytic treatment interruption (ATI) in people living with human immunodeficiency virus-1 (HIV-1, PLWH) who have initiated or will initiate antiretroviral therapy (ART) during acute HIV-1 infection (AHI).
This description comes directly from the study's public registry record.
Kiat Ruxrungtham, MD · +66 02 256 4579 · rkiatchula@gmail.com
Donn Colby, MD, MPH · 206-419-0779 · Ddcolby@hivresearch.org
Always discuss trial participation with your own doctor first.
| The Faculty of Medicine, Chulalongkorn University/ King Chulalongkorn Memorial Hospital | Pathum Wan, Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06484335